🔗 Share this article

A shadow market for unlicensed weight-loss drugs is propelled by social media fitness personalities and vendors on communication apps, based on new investigations.

Experimental Drug Gaining Traction Via Social Media

The experimental drug, which is still in clinical trials, is being advertised by online personalities for its supposed fat-burning properties. Followers are urged to contact these profiles directly for supplier links, while also receiving promotional offers.

Thriving Commerce on Social Networks

Separately, a flourishing trade exists on messaging services, where communities with thousands of participants share “before and after” photos, injection guides and claims of rapid British shipping. Vendors promote the drug there before redirecting customers to other platforms for purchases.

Learning About The Experimental Drug

Retatrutide is an experimental injection created by US drugmaker Eli Lilly. The drug affects three gut hormones – GLP-1, GIP and glucagon. Preliminary studies indicate it could help patients lose up to a quarter of their total weight. Referred to as the “triple G”, the substance is being promoted online as the successor to Ozempic.

Medical Professionals Express Concerns

Nevertheless, physicians and pharmacists have warned that the sale of what remains an unlicensed drug in the United Kingdom is worrisome and could lead to users injecting products of unknown origin.

Several experts stated the demand for retatrutide could be connected to the rising cost of licensed slimming treatments such as Mounjaro.

Legal Position and Implementation

Marketing the unapproved drug on social media or Telegram is prohibited in the United Kingdom, as it is an unlicensed drug that must not be marketed or distributed for personal consumption under the Human Medicines Regulations 2012.

Several influencers try to circumvent the regulations by referring to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled drug, but advertising and supply can still breach pharmaceutical, advertising, and customer regulations, potentially leading to fines, legal action or imprisonment.

Service Response and Content Elimination

According to the social media company, the service has taken down violative content and prohibited associated keywords and search suggestions. The organization said it was committed to maintaining the service safe and allocating resources in strengthening enforcement strategies.

Online Trading Operations

Research also found groups with up to nine thousand participants selling the experimental drug using the platform's built-in search feature, which operates like a public directory. Typing “retatrutide” instantly displays channels with numerous of users, populated with images of weight loss, positive testimonials and detailed instructions for mixing or injecting at home.

After moments of entering one group, a vendor posted contact information, where most transactions occur. The seller provided an guidebook and guaranteed shipping within 48 hours. When asked whether the substance was genuine, one vendor responded: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. None asked about weight, medical conditions or previous experience.

Item Information and Pricing

Within these communities, messages display dark colored parcels with postal service labels, claiming to include new batches. One communication stated: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, prepared at home with purified liquid, or ready-to-use injectors typically sold at £160 for 20 milligrams. When questioned how much time a pen should be used, vendors give contradictory responses ranging from a several days to “depends on your body”.

Service Moderation and Security Measures

A spokesperson for Telegram stated it regularly moderated harmful material on its service including material that encouraged the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Cautions

“Individuals are administering materials they can’t verify. Although the science behind retatrutide is sound, these online versions may not include what they claim,” said Jason Murphy, the head of pharmacy at Chemist4U.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in demand to recent price rises for authorized slimming drugs such as Mounjaro. “With costs increasing, patients are using social media. But fake treatments are extremely risky. You can’t be certain what’s contained or whether the conditions they were made in was clean,” she explained.

Her staff has already seen individuals injured by self-injection from unverified sources. “We understand the disappointment, but purchasing from Telegram or communication platforms is gambling with your health,” said Wyllie. “These materials could be impure or improperly measured.”

Manufacturer Statement

A representative from Eli Lilly stated the substance was in third stage clinical trials and had not been evaluated or approved by any regulatory agency anywhere in the world. “Therefore at this time no one can sell [it] for human use,” they said, noting that any product “falsely representing itself as a Lilly investigational substance not yet authorized … may subject patients to possibly significant health risks”.